Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27875053 | 0.97 | IDO1 (0.56) | IDO1AGXTKDM4ESMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL581098 | 0.95 | IDO1 (0.57) | IDO1AGXTKDM4ESMN1; SMN2ALDH1A1 | |
| Bromide SCHEMBL582511 | 0.80 | PSEN1 (0.43) | IDO1AGXTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL3298107 | 0.79 | IDO1 (0.58) | IDO1AGXTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL7700904 | 0.79 | IDO1 (0.58) | IDO1AGXTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL284327 | 0.77 | IDO1 (0.56) | IDO1AGXTKDM4ESMN1; SMN2ALDH1A1 | |
| Bromide SCHEMBL28745183 | 0.76 | HTR2A (0.41) | IDO1SMN1; SMN2ALDH1A1HTR2AHTR2C | |
| SCHEMBL1503215 | 0.75 | IDO1 (0.54) | IDO1AGXTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL113852 | 0.75 | IDO1 (0.59) | IDO1AGXTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL93024 | 0.75 | IDO1 (0.54) | IDO1AGXTKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025056518-A1 | 5,6-DISUBSTITUTED ALKYL 1H AND 2H-INDAZOLES AS DUAL BUTYRYLCHOLINESTERASE AND p38α MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | UNIVERZA V LJUBLJANI (SI) | 2025-03-20 | — | — | WO | disclosed |
| US-9409871-B2 | Pyridazinyl derivatives as SMO inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2665711-A1 | PICOLINAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-8481542-B2 | Pyridazinyl derivatives as smo inhibitors | NOVARTIS AG (CH) | 2013-07-09 | — | — | US | disclosed |
| EP-2318389-B1 | PYRIDAZINE DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| WO-2012100135-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| US-7049325-B2 | Quinoline derivatives as anti-inflammatory agents | SYNTEX (U.S.A.) LLC (US) | 2006-05-23 | — | — | US | disclosed |
| WO-2006045429-A1 | HALOGEN SUBSTITUTED BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| US-20060084677-A1 | Quinoline derivatives as anti-inflammatory agents | BROKA CHRIS A | 2006-04-20 | — | — | US | disclosed |
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | US | disclosed |
| WO-2006018735-A2 | TRIAZOLOPYRIDINE COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006018727-A2 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005042491-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| EP-1313707-A1 | QUINOLINE DERIVATIVES AS ANTI-INFLAMMATION AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| US-20020082276-A1 | Quinoline derivatives as anti-inflammatory agents | SNYTEX (U.S.A.) LLC | 2002-06-27 | — | — | US | disclosed |
| WO-2002012192-A1 | QUINOLENE DERIVATIVES AS ANTI-INFLAMMATION AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084677-A1 | Quinoline derivatives as anti-inflammatory agents | NR5A2, PTGER4, IL5 | IDO1 1200/4885AGXT 4595/4885KDM4E 1663/4885 |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ALK, PKN2, ERBB2 | IDO1 2470/4885AGXT 2711/4885KDM4E 1944/4885 |
| US-20020082276-A1 | Quinoline derivatives as anti-inflammatory agents | CNR1, CNR2, PTGER4 | IDO1 324/4885AGXT 3798/4885KDM4E 1014/4885 |
| US-20060084801-A1 | Halogen substituted imidazol[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | GABRA1, GABRA4, GABRA5 | IDO1 1583/4885AGXT 2357/4885KDM4E 3573/4885 |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | SMO, SHH, GLI1 | IDO1 1994/4885AGXT 3877/4885KDM4E 325/4885 |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | SMO, GLI1, SHH | IDO1 1102/4885AGXT 3779/4885KDM4E 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.